PPBT — PURPLE BIOTECH LTD.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1614744 ·
Last close
$1.71
Market Cap
$2.78M
52W High
$8.90
52W Low
$0.91
ADV30
29,190
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -1,299,000 441,000 14,166,000 5,236,000 1,953,000
Mar 2026 0 — -2,251,000 -86,000 14,417,000 5,567,000 4,753,000
Dec 2025 0 — -2,963,000 -23,545,000 17,572,000 8,717,000 7,913,000
Sep 2025 0 — -1,367,000 -1,303,000 39,061,000 9,592,000 6,246,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,758,000
Investing CF
$314,000
Financing CF
$7,918,000
CapEx
—
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-381.60
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-170,724,000
Inventory
—
Receivables
$155,000
ST Investments
$869,000
EBIT TTM
$-24,527,000
Pretax Income TTM
$-24,595,000
Interest Exp TTM
$68,000
Analysts
1

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -6,976,000 -26,386,000 17,572,000 7,913,000 9,714,000 -5,656,000
Dec 2024 0 -10,803,000 -7,240,000 37,038,000 4,127,000 32,860,000 -14,367,000
Dec 2023 0 -22,271,000 -19,880,000 44,302,000 10,005,000 34,207,000 -19,925,000
Dec 2022 0 -22,603,000 -21,668,000 54,622,000 7,524,000 46,911,000 -16,735,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.01

Peers — same industry

TickerNameMarket CapLastDaily %
DRMA Dermata Therapeutics, Inc. $2.81M $0.57 —
NRSN NeuroSense Therapeutics Ltd. $2.86M $1.51 —
GELS Gelteq Ltd $2.88M $0.27 —
MDCX Medicus Pharma Ltd. $2.89M $1.52 —
BIXT BIOXYTRAN, INC $2.66M $0.02 —

News headlines (Yahoo Finance, 1h cache)

Purple Biotech Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-17 12:55 · Yahoo
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
2026-10-29 13:00 · Yahoo
Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection
2026-09-02 15:07 · Yahoo
Top Midday Gainers
2026-09-02 17:50 · Yahoo
New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
2026-09-02 11:30 · Yahoo
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-15 11:00 · Yahoo
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
2026-04-23 11:00 · Yahoo
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
2026-04-27 11:00 · Yahoo
Purple Biotech Reports Second Quarter 2026 Financial Results
2026-08-07 11:00 · Yahoo
Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT)
2026-06-11 14:38 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.